Please login to the form below

Not currently logged in
Email:
Password:

Forixiga

This page shows the latest Forixiga news and features for those working in and with pharma, biotech and healthcare.

AZ gets US approval for diabetes combo Qtern

AZ gets US approval for diabetes combo Qtern

Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga (dapagliflozin).

Latest news

  • EU clears AZ's FDA-rejected diabetes combination EU clears AZ's FDA-rejected diabetes combination

    Qtern combines the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) with SGLT2 inhibitor Farxiga/Forixiga (saxagliptin), and is the second drug of its type on the market after

  • FDA rejects AZ's diabetes combination FDA rejects AZ's diabetes combination

    The combination of DPP-4 inhibitor saxagliptin - sold by AZ as Onglyza - and SGLT2 inhibitor dapagliflozin (marketed as Farxiga/Forixiga) is considered to be a key component of the company's

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics